Toronto Dominion Bank Grows Holdings in Insulet Co. (NASDAQ:PODD)

Toronto Dominion Bank grew its position in Insulet Co. (NASDAQ:PODD) by 55.2% in the fourth quarter, HoldingsChannel reports. The fund owned 36,486 shares of the medical instruments supplier’s stock after acquiring an additional 12,984 shares during the quarter. Toronto Dominion Bank’s holdings in Insulet were worth $9,526,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Horizon Investments LLC increased its stake in shares of Insulet by 3.1% in the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 42 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after buying an additional 43 shares in the last quarter. Wilmington Savings Fund Society FSB increased its position in shares of Insulet by 9.6% in the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock valued at $140,000 after buying an additional 47 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its stake in shares of Insulet by 2.3% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier’s stock worth $552,000 after buying an additional 48 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its position in shares of Insulet by 5.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,050 shares of the medical instruments supplier’s stock valued at $274,000 after buying an additional 50 shares in the last quarter.

Insulet Price Performance

NASDAQ:PODD opened at $327.47 on Wednesday. Insulet Co. has a one year low of $170.67 and a one year high of $329.00. The stock has a market cap of $23.05 billion, a PE ratio of 56.56, a P/E/G ratio of 3.62 and a beta of 1.26. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The stock has a 50 day moving average price of $267.35 and a 200 day moving average price of $267.99.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.21. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $569.00 million during the quarter, compared to analysts’ expectations of $543.20 million. During the same period in the prior year, the business earned $0.73 EPS. The firm’s quarterly revenue was up 28.8% on a year-over-year basis. Equities research analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Barclays boosted their price target on shares of Insulet from $234.00 to $266.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 30th. Wolfe Research upgraded shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $350.00 target price on the stock in a research report on Tuesday, May 13th. Wells Fargo & Company set a $322.00 price target on shares of Insulet in a research report on Monday, April 28th. Oppenheimer raised their price target on shares of Insulet from $312.00 to $324.00 and gave the company an “outperform” rating in a research note on Friday, May 9th. Finally, Citigroup boosted their price objective on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $306.53.

Insider Activity at Insulet

In related news, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP John W. Kapples sold 5,278 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the completion of the transaction, the senior vice president now owns 23,180 shares of the company’s stock, valued at $7,382,134.60. The trade was a 18.55% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.